Notícias e Atividades da Taiho Oncology

A Taiho Oncology pertence à Otsuka Holdings.

Otsuka Holdings é uma das ...

• Forbes Global 2000 (#654);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Otsuka Holdings é uma empresa listada sob o símbolo 4578 (JP).

Otsuka Holdings tem presença direta em 11 países.

Otsuka Holdings possui 23 subsidiárias incluindo Araris Biotech, Cambridge Isotope Laboratories e Interpharma.

Eles estão dentro:

• Farmacêutica46%
• Equipamentos Médicos29%
• Outro25%

Veja o organograma con seus 22 executivos principais

Biografias mais buscadas da Taiho Oncology

• Peter Melnyk, President & Chief Executive Officer
• Volker Wacheck, Senior Vice President and Head of Clinical Develop...
• Chris Jewell, Senior Vice President and General Counsel

Recentes movimentos de executivos em Taiho Oncology

• Tim Whitten, President and Chief Executive Officer, deixou a Companhia  (Notícia publicada em 30 de janeiro de 2026).
• Peter Melnyk antes President & Chief Operating Officer, foi promovido a President & Chief Executive Officer  (Notícia publicada em 30 de janeiro de 2026).
• Peter Melnyk, ingressou na Companhia como President & Chief Operating Officer  (Notícia publicada em 21 de janeiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Taiho Oncology.

Otsuka Holdings possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott
• Jonathan Leff - Director da Larimar Therapeutics

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Taiho Oncology

• Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib f
• Taiho Oncology Announces 14 Presentations, Including Six Oral Presentations, at the 67th American Society of Hematology Annual Meeting and Exposition
• Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
• Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
• Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025
• Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
• Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients wit
• Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
• Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
• Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
• View more press releases Close

Redes sociais sobre Taiho Oncology

• Taiho Oncology na Wikipedia, Google News e Yahoo Finance
• Taiho Oncology na LinkedIn, X (Twitter) e YouTube